Dasatinib (SprycelÒ, Bristol‑Myers Squibb Pharma), also a second generation TKI, inhibits the tyrosine kinase activity of the BCR-ABL protein. It was developed to be effective in imatinib-resistant CML, and for patients with side effects to imatinib.
It is approved for:
- Newly‑diagnosed patients in any of the phases of CML
- Patients with resistance or intolerance to previous treatments
